Physician profile
Emile Daoud
NPI 1124023437
$46,248.48
in general payments reported to CMS, 2019-2025
18 companies · $2,825 in 2025
The $2,825 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,299 · 2020: $1,976 · 2021: $4,566 · 2022: $9,312 · 2023: $15K · 2024: $7,407 · 2025: $2,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $4,474 · Food and Beverage: $4,317 · Honoraria: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,503.09 |
| Travel and Lodging | $4,474.30 |
| Food and Beverage | $4,317.41 |
| Honoraria | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $24,889.96 | 2019-2025 | Carto 3, Nuvision Ice Catheter |
| Biotronik INC. | $5,719.41 | 2019-2020 | |
| Medtronic, INC. | $3,451.90 | 2021-2025 | Affera Mapping System, Pulseselect, Selectsecure |
| Abbott Laboratories | $2,899.83 | 2019-2025 | Aveir, Ensite Precision, Gallant |
| Boston Scientific Corporation | $2,192.49 | 2019-2025 | Watchman Access System, General - Therapies, General - Tachy |
| Altathera Pharmaceuticals LLC | $2,137.49 | 2022-2024 | Sotalol Hydrochloride |
| Medical Device Business Services, INC. | $2,089.62 | 2022-2023 | Carto 3 |
| Cardiva Medical, INC. | $1,618.80 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic Vascular, INC. | $1,002.47 | 2020 | |
| Acutus Medical, INC. | $101.92 | 2019 | |
| Atricure, INC. | $38.84 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.73 | 2025 | |
| Merck Sharp & Dohme LLC | $16.07 | 2024 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $14.98 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $14.80 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.43 | 2025 | |
| Alnylam Pharmaceuticals INC. | $13.74 | 2025 | Onpattro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$351,370.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emile Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.